RETRACTED ARTICLE: Biotinylated naringenin intensified anticancer effect of gefitinib in urethane-induced lung cancer in rats: favourable modulation of apoptotic regulators and serum metabolomics

Parashar, Poonam; Tripathi, Chandra Bhushan; Arya, Malti; Kanoujia, Jovita; Singh, Mahendra; Yadav, Abhishek; Kumar, Amit; Guleria, Anupam; Saraf, Shubhini A.

doi:10.1080/21691401.2018.1505738

Cited by 30 publications

(9 citation statements)

References 46 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, the Naringenin‐SLNs prepared by Ji et al, was not toxic to A549 cell at a concentration range of 1–50 µg/ml for 72 hr (Ji et al., 2016). In contrast, Parashar et al, reported that biotinylated Naringenin significantly decreased the proliferation of A549 cell with a IC 50 value of 37.46 ± 0.86 µM (Parashar et al., 2018). Our Naringenin‐loaded LCNs formulation was more potent than Naringenin‐SLNs, biotinylated Naringenin, and powder Naringenin in terms of inhibiting the proliferation of the A549 cells.…”

Section: Discussionmentioning

confidence: 94%

Anti‐inflammatory and anticancer activities of Naringenin‐loaded liquid crystalline nanoparticles in vitro

et al. 2020

View full text Add to dashboard Cite

In this study, we had developed Naringenin-loaded liquid crystalline nanoparticles (LCNs) and investigated the anti-inflammatory and anticancer activities of Naringenin-LCNs against human airway epithelium-derived basal cells (BCi-NS1.1) and human lung epithelial carcinoma (A549) cell lines, respectively. The anti-inflammatory potential of Naringenin-LCNs evaluated by qPCR revealed a decreased expression of IL-6, IL-8, IL-1β, and TNF-α in lipopolysaccharide-induced BCi-NS1.1 cells. The activity of LCNs was comparable to the positive control drug Fluticasone propionate (10 nM). The anticancer activity was studied by evaluating the antiproliferative (MTT and trypan blue assays), antimigratory (scratch wound healing assay, modified Boyden chamber assay, and immunoblot), and anticolony formation activity in A549 cells. Naringenin LCNs showed promising antiproliferative, antimigratory, and anticolony formation activities in A549 cells, in vitro. Therefore, based on our observations and results, we conclude that Naringenin-LCNs may be employed as a potential therapy-based intervention to ameliorate airway inflammation and to inhibit the progression of lung cancer. Practical applications Naringenin was encapsulated into liquid crystalline nanoparticles, thus, attributing to their sustained-release nature. In addition, Naringenin-loaded LCNs efficiently reduced the levels of pro-inflammatory markers, namely, IL-1β, IL-6, TNF-α, and IL-8. In addition, the Naringenin-loaded LCNs also possess potent anticancer activity, when tested in the A549 cell line, as revealed by the inhibition of proliferation and migration of cells. They also attenuated colony formation and induced apoptosis in the A549 cells. The findings from our study could form the basis for future research that may be translated into an in vivo model to validate the possible therapeutic alternative for lung cancer using Naringenin-loaded LCNs. In addition, the applications of

show abstract

Section: Discussionmentioning

confidence: 94%

Anti‐inflammatory and anticancer activities of Naringenin‐loaded liquid crystalline nanoparticles in vitro

et al. 2020

View full text Add to dashboard Cite

show abstract

“…prostate, pancreatic, colon, breast, and gastric cancer (Song et al, 2016;Lim et al, 2017;Wang et al, 2019a) sensitizing chemotherapy CDKN2A, BCL2, CASP3/9, BAX, PTK2, MAPK14 lung and pancreatic cancer (Parashar et al, 2018;Lee et al, 2019) inhibiting metabolism AKT1, GTF2H2, MAP2K1/2, MAPK1, NFKB1, PIK3CA breast cancer (Harmon and Patel, 2004) enhancing immunity GZMB, ID2, IFNG, IRF2, SMAD3/7 lung cancer and melanoma (Lian et al, 2018) Naringin anti-proliferation AKT1, BIRC5, CDKN1A, CTNNB1, EGFR, MAPK1, MIR126, MTOR, NFKB, PIK3CA, VCAM1…”

Section: Discussionmentioning

confidence: 99%

Mapping Pharmacological Network of Multi-Targeting Litchi Ingredients in Cancer Therapeutics

Cao

Han

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Considerable pharmacological studies have demonstrated that the extracts and ingredients from different parts (seeds, peels, pulps, and flowers) of Litchi exhibited anticancer effects by affecting the proliferation, apoptosis, autophagy, metastasis, chemotherapy and radiotherapy sensitivity, stemness, metabolism, angiogenesis, and immunity via multiple targeting. However, there is no systematical analysis on the interaction network of "multiple ingredients-multiple targets-multiple pathways" anticancer effects of Litchi. In this study, we summarized the confirmed anticancer ingredients and molecular targets of Litchi based on published articles and applied network pharmacology approach to explore the complex mechanisms underlying these effects from a perspective of system biology. The top ingredients, top targets, and top pathways of each anticancer function were identified using network pharmacology approach. Further intersecting analyses showed that Epigallocatechin gallate (EGCG), Gallic acid, Kaempferol, Luteolin, and Betulinic acid were the top ingredients which might be the key ingredients exerting anticancer function of Litchi, while BAX, BCL2, CASP3, and AKT1 were the top targets which might be the main targets underling the anticancer mechanisms of these top ingredients. These results provided references for further understanding and exploration of Litchi as therapeutics in cancer as well as the application of "Component Formula" based on Litchi's effective ingredients.

show abstract

“…Co-administration of gefinitib and naringenin NPs promoted enhanced cell apoptosis while regulating the serum metabolites and biochemical parameters to normal levels. The cotherapy caused a remarkable increase in the pro-apoptotic proteins (BAX and caspase-9) and reduced anti-apoptotic proteins (MMP-9, P-16 and Bcl-2) (Parashar et al, 2018b). Parteek and coworkers also indicated that, entrapment of naringenin into hyaluronic acid-chitosan-PCL NPs, by utilizing layer by layer technique, is effective in targeting lung cancer cells.…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Molecular mechanisms of action of naringenin in chronic airway diseases

Chin

Hon

Chellappan

et al. 2020

European Journal of Pharmacology

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

RETRACTED ARTICLE: Biotinylated naringenin intensified anticancer effect of gefitinib in urethane-induced lung cancer in rats: favourable modulation of apoptotic regulators and serum metabolomics

Cited by 30 publications

References 46 publications

Anti‐inflammatory and anticancer activities of Naringenin‐loaded liquid crystalline nanoparticles in vitro

Anti‐inflammatory and anticancer activities of Naringenin‐loaded liquid crystalline nanoparticles in vitro

Mapping Pharmacological Network of Multi-Targeting Litchi Ingredients in Cancer Therapeutics

Molecular mechanisms of action of naringenin in chronic airway diseases

Contact Info

Product

Resources

About